Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite

Veeva Systems (VEEV) recently announced that Gilead Sciences has committed to using its Veeva Vault CRM, highlighting the company's expansion in the pharmaceutical CRM space through advanced AI technology. This development comes as broader market indices hit record highs, driven by stable inflation data and hopes of interest rate cuts. With Veeva's stock rising 1.35% last week, its performance mirrored the 1.4% gain in the broader market. The momentum suggests that the Gilead partnership may have synergized with general market optimism, boosting investor sentiment around the company's growth and innovation in its industry.

Buy, Hold or Sell Veeva Systems? View our complete analysis and fair value estimate and you decide.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

The collaboration with Gilead Sciences enhances Veeva Systems' presence in pharmaceutical CRM, potentially leading to wider product adoption and revenue growth. This aligns with the narrative of resolving interoperability challenges and embedding AI, supporting future revenue and margin expansion. The significant three-year total return of 57.64% exemplifies strong historical performance, providing context to the current share price movement and analyst valuations. Over the past year, Veeva's stock performance surpassed both the US Healthcare Services industry, which returned 16.8%, and the broader US Market with a 19.1% return.

For future projections, analysts expect Veeva’s revenues to grow by 12.8% annually over the next three years, with earnings potentially reaching US$1.3 billion by September 2028. This growth would necessitate a PE ratio adjustment from 57.2x to 50.3x by 2028. The recent share price increase to US$274.60 positions it at a 15.34% discount to the consensus target price of US$316.71, suggesting potential room for appreciation. The company's enhancing AI capabilities in its platforms create opportunities for increased pricing power and improved profitability, underpinning these optimistic forecasts.

Our valuation report here indicates Veeva Systems may be overvalued.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com